- cafead   Mar 20, 2022 at 11:22: PM
via
article source
- Pfizer and Novartis have licensed Voyager's promising AAV capsid technology.
- Voyager faces significant risks, especially with no candidates in clinical studies yet.
- A wait-and-see approach is probably the best one for now with the biotech stock.
article source